) The Clinical Trials Core is an integral part of the CCC. The CTO is a center of multi-disciplinary clinical trials support activity, serving the needs of cancer researchers throughout the Cancer Center, in the academic Departments of Medicine, Radiation Oncology, Gynecology, Pediatrics, Surgery, Urology, Otolaryngology, and Neurology. The scope of the CTO activities includes national cooperative groups, industrial, NCI sponsored, multi-institutional and local, investigator initiated studies. The objective of the Core is to enhance the efficiency and cost effectiveness of the implementation and conduct of clinical trials by providing CCC investigators with services including patient recruitment and registration to trials; data collection; review of all new cancer-related trials; annual review of all ongoing trials; preparation of protocol specific consent forms and protocol submission to IRB; advisory function for investigators regarding protocol guidelines; centralized repository of all clinical trials; assurance of Investigator Compliance with Good Clinical Practice Guidelines; assistance with protocol development, writing and budget preparation. In collaboration with the Biostatistics Core, all cancer related protocols and annual protocol renewals are reviewed by the Cancer Center Clinical Trials Committee prior to submission to the Wayne State IRB. Overall, 33 individuals provide service as members of the Clinical Trials Core, supporting more than 400 active protocols. These activities have resulted in consistent increases in accrual to clinical trials over the years with excellent representation of minorities and women. Protocols are available via the CCC Web site, replacing protocol books, increasing the ease of access to protocol information with associated cost savings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-22S1
Application #
6503923
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-09-27
Project End
2001-11-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Colacino, Justin A; Azizi, Ebrahim; Brooks, Michael D et al. (2018) Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports 10:1596-1609
Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40
Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249
Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294

Showing the most recent 10 out of 826 publications